Rhythm Pharmaceuticals Reports 3Q 2026 Revenue of $92.13 Million
Revenue rose 79.6% year over year to $92.13 million. Net loss narrowed to $42.35 million from $54.28 million, and diluted loss per share improved to $0.61 from $0.82.
Rhythm Pharmaceuticals reported third-quarter 2026 revenue of $92.13 million, up 79.6% from the prior-year quarter. Net loss narrowed to $42.35 million from $54.28 million, while diluted loss per share improved to $0.61 from $0.82.Financial Highlights¹ Reported as “Total revenues”. ² Reported as “N…